Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Coxiella burnetii-specific CD4+ T cells are a specialized population of helper T lymphocytes that play a critical role in the adaptive immune response against the intracellular bacterium Coxiella burnetii, the causative agent of Q fever (Scholzen et al., 2019, Journal of Immunology). These cells recognize specific bacterial peptide fragments, known as epitopes, which are processed and presented on the surface of antigen-presenting cells by Human Leukocyte Antigen (HLA) class II molecules (Long et al., 2019, Frontiers in Immunology). Upon recognition of these HLA-peptide complexes via their T-cell receptors (TCRs), the CD4+ T cells become activated and secrete pro-inflammatory cytokines, most notably interferon-gamma (IFN-gamma). This cytokine signaling is essential for activating macrophages to restrict the intracellular replication of C. burnetii (CDC, 2021). In the context of drug and vaccine development, these T cells and their corresponding HLA-presented epitopes are primary targets for the design of next-generation subunit vaccines aimed at providing protective immunity without the adverse reactogenicity associated with traditional whole-cell vaccines like Q-Vax.
Activation of CD4+ T cells through T-cell receptor (TCR) recognition of Coxiella burnetii-derived peptide epitopes presented on HLA class II molecules, leading to the production of interferon-gamma (IFN-gamma) and subsequent macrophage activation for bacterial clearance.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Coxiella burnetii-specific CD4+ T cell.